lilly tirzepatide approval FDA for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli FDA approves Eli Lilly's Zepbound,
Description
Stay tuned for a fresh look and even more ways to support your wellness journey

Treatment focuses on managing symptoms and addressing the underlying metabolic and hormonal imbalances in the body

What is GLP-1 and how does it work

Retatrutide appears to push the boundaries even further
Any pediatric use would be off-label and require careful physician oversight
